€0.00
-0.00 (-7.69%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OXUR.BR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate THR-149 Treatment for Diabetic Macular OedemaNCT04527107Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the studyRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg | Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema | 135 | 2023-09-28actual | 2023-11-27 |
| A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.NCT05063734results2023-08-18Change From Baseline in BCVA ETDRS Letter Score, at Month 3, in Treatment-naïve Subjects in Part B of the StudyRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Based on data obtained in Part A, there was insufficient evidence of efficacy on the key outcome measures. As a result, the study was not advanced to Part B. | Drug: THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept | Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema | 16 | 2022-06-29actual | 2023-08-18 |
| A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)NCT03499223Change from baseline in BCVARandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: Ranibizumab 0.5mg, THR-317 8mg, Sham injection | Diabetes Mellitus, Diabetic Retinopathy, Macular Edema | 70 | 2019-07-18actual | 2019-08-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19